Sutimlimab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody designed to selectively inhibit the classical complement pathway. It specifically binds to complement component 1s (C1s), a serine protease involved in the activation of the classical complement cascade. Sutimlimab is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells.
Sutimlimab is the active substance of Enjaymo and is used in the treatment of hemolytic anemia associated with cold agglutinin disease (CAD) in adults. The European Medicines Agency lists sutimlimab under ATC code L04AJ04 and classifies it within the immunosuppressant pharmacotherapeutic group.
Sutimlimab is a recombinant humanized IgG4 monoclonal antibody directed against human complement C1s. The molecule consists of two heterodimers, with each heterodimer containing one heavy chain and one light chain. Each heavy chain contains 445 amino acids and each light chain contains 216 amino acids.
The predicted molecular weight of the non-glycosylated native molecule is approximately 144,813 Da based on its amino-acid sequence. The marketed antibody has a molecular weight of approximately 147 kDa, reflecting its glycosylated biologic structure.
CAS Number: 2049079-64-1
Molecular Formula: C6436H9938N1700O2013S46
Molecular Weight: approximately 144.813 kDa for the predicted non-glycosylated native molecule; approximately 147 kDa for the antibody drug substance/product.
Sutimlimab contains engineered sequence modifications including S241P for stabilization of the core-hinge region and L248E, which reduces Fc-gamma receptor binding. The molecule is glycosylated at heavy-chain residue N295.
Sutimlimab selectively binds to C1s and inhibits its serine-protease activity. C1s normally participates in the cleavage of complement component C4 during activation of the classical complement pathway. By inhibiting C1s, sutimlimab suppresses classical-pathway activation and complement-mediated hemolysis.
Importantly, sutimlimab selectively targets the classical pathway and does not inhibit the lectin or alternative complement pathways. This mechanism helps reduce C1-activated destruction of red blood cells in patients with cold agglutinin disease.
Sutimlimab is primarily associated with the treatment of cold agglutinin disease (CAD), a rare autoimmune hemolytic anemia in which complement activation contributes to destruction of red blood cells.
The approved therapeutic use is based on its ability to inhibit classical complement pathway-mediated hemolysis. In the European Union, Enjaymo (sutimlimab) is indicated for treatment of hemolytic anemia in adult patients with cold agglutinin disease.
As a recombinant monoclonal-antibody API, sutimlimab requires biologic-specific quality characterization rather than the conventional testing profile used for small-molecule APIs.
Typical quality evaluation for a monoclonal-antibody drug substance may include:
Specific numerical acceptance criteria are product- and manufacturing-process dependent and should be taken from the applicable approved specification rather than being inferred from small-molecule API standards.
Swapnroop Drugs and Pharmaceuticals is an India-based pharmaceutical manufacturer providing API and pharmaceutical-development capabilities for international markets. For specialized biological APIs such as Sutimlimab, quality systems, controlled manufacturing processes, analytical characterization, documentation, and appropriate storage conditions are essential considerations.
Sutimlimab is a complex recombinant IgG4 monoclonal antibody, and its manufacture and quality evaluation require biologics-specific controls and characterization. Regulatory documentation identifies the active substance as being produced in CHO cells using recombinant DNA technology followed by chromatographic purification.
Sutimlimab is a biologic active substance and should be handled according to the validated storage and transportation requirements established for the specific drug-substance formulation.
The finished Enjaymo product is supplied as a sterile solution for intravenous infusion at 50 mg/mL in a single-dose vial. The marketed presentation contains 1,100 mg of sutimlimab in 22 mL.
For API supply, packaging configuration, temperature conditions, shipping controls, and shelf-life should follow the approved product specification and validated stability data.
Documentation available for pharmaceutical API projects may include:
Sutimlimab is a specialized recombinant humanized IgG4 monoclonal antibody targeting C1s of the classical complement pathway. Its selective mechanism makes it an important biologic therapy for complement-mediated hemolysis associated with cold agglutinin disease. Because Sutimlimab is a complex biological molecule, identity, purity, potency, structural characterization, and process-related impurity controls are particularly important when evaluating the API.
Swapnroop Drugs and Pharmaceuticals supports pharmaceutical customers with quality-focused API manufacturing and documentation for international requirements.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |